clinical trial · NCT06297226
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company·phase2·recruiting·n = 230
Multiple MyelomaArlocabtagene Autoleucel
brief summary
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
started
Mar 21, 2024
primary completion
Jun 30, 2027
completion
Jun 30, 2032
last updated
Feb 10, 2026
official title
A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol